-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AXDuhe7RnJRurLokfbs3MDnAaUy94iAneDdBZuG2NRo/RJkFDymH1wG8jlN2twOo CkTroyFuOWeW7pWUW4DExA== 0000950123-11-015335.txt : 20110218 0000950123-11-015335.hdr.sgml : 20110218 20110217213857 ACCESSION NUMBER: 0000950123-11-015335 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20110218 DATE AS OF CHANGE: 20110217 EFFECTIVENESS DATE: 20110218 FILER: COMPANY DATA: COMPANY CONFORMED NAME: US ONCOLOGY INC CENTRAL INDEX KEY: 0000943061 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] IRS NUMBER: 841213501 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 000-26190 FILM NUMBER: 11622513 BUSINESS ADDRESS: STREET 1: 16825 NORTHCHASE DR STREET 2: STE 1300 CITY: HOUSTON STATE: TX ZIP: 77060 BUSINESS PHONE: 2818732674 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN ONCOLOGY RESOURCES INC /DE/ DATE OF NAME CHANGE: 19950327 15-12G 1 f58394e15v12g.htm 15-12G e15v12g
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTION 13 AND 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number: 0-26190
US Oncology, Inc.
(Exact name of registrant as specified in its charter)
10101 Woodloch Forest
The Woodlands, Texas 77380, (281) 863-1000
(Address, including zip code, and telephone number, including area code,
of registrant’s principal executive offices)
9.125% Senior Secured Notes Due 2017
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file
reports under section 13(a) or 15(d) remains)
          Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
     
Rule 12g-4(a)(1)
  o
Rule 12g-4(a)(2)
  o
Rule 12h-3(b)(1)(i)
  þ
Rule 12h-3(b)(1)(ii)
  o
Rule 15d-6
  o
          Approximate number of holders of record as of the certification or notice date: None
          Pursuant to the requirements of the Securities Exchange Act of 1934, US Oncology, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
         
Date: February 17, 2011  US ONCOLOGY, INC.
 		  
  By:   /s/ Willie C. Bogan    
    Willie C. Bogan   
    Vice President and Secretary   
 
 
 

 -----END PRIVACY-ENHANCED MESSAGE-----